Pieris Pharmaceuticals Inc. (PIRS) Rating Reiterated by Oppenheimer Holdings Inc.
Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)‘s stock had its “outperform” rating reissued by equities researchers at Oppenheimer Holdings Inc. in a report issued on Wednesday. They presently have a $10.00 price target on the stock. Oppenheimer Holdings Inc.’s price target suggests a potential upside of 495.24% from the stock’s current price.
Separately, Roth Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Pieris Pharmaceuticals in a research note on Wednesday.
Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.68 on Wednesday. Pieris Pharmaceuticals has a one year low of $1.26 and a one year high of $3.08. The company’s market capitalization is $72.34 million. The firm’s 50 day moving average price is $1.63 and its 200-day moving average price is $1.79.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Pieris Pharmaceuticals had a negative return on equity of 52.21% and a negative net margin of 346.01%. The company had revenue of $1.07 million for the quarter. Equities analysts forecast that Pieris Pharmaceuticals will post ($0.55) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of PIRS. BlackRock Fund Advisors acquired a new position in Pieris Pharmaceuticals during the second quarter worth $113,000. Frontier Wealth Management LLC acquired a new position in Pieris Pharmaceuticals during the second quarter worth $137,000. Sabby Management LLC raised its position in Pieris Pharmaceuticals by 132.7% in the first quarter. Sabby Management LLC now owns 175,000 shares of the company’s stock worth $333,000 after buying an additional 99,792 shares during the last quarter. BVF Inc. IL acquired a new position in Pieris Pharmaceuticals during the second quarter worth $389,000. Finally, Lombard Odier Asset Management USA Corp raised its position in Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock worth $5,099,000 after buying an additional 533,965 shares during the last quarter. 45.79% of the stock is currently owned by institutional investors and hedge funds.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.